Inlyta Tablet, Film Coated
Product Images NDC 0069-0151

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Inlyta (NDC 0069-0151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Inlyta 01)

Chemical structure of axitinib, the active ingredient in INLYTA tablets. The structure features multiple aromatic rings, including a benzene ring connected to sulfur, and a fused bicyclic system with nitrogen atoms, representing the molecular framework of axitinib.*

FDA Label Image

Figure 1 (Inlyta 02)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for the maximum concentration (Cmax) and area under the curve (AUC) of INLYTA (axitinib) in various population conditions, including strong CYP3A4/5 inhibitors (Ketoconazole), inducers (Rifampin), antacid (Rabeprazole), and different levels of hepatic impairment. Recommendations are provided for dose adjustments or avoidance based on these changes.*

FDA Label Image

Figure 2 (Inlyta 03)

A Kaplan-Meier survival curve showing the probability of progression-free survival (PFS) over time in months for two treatment groups: INLYTA + Avelumab and Sunitinib. The graph includes the number of patients at risk at various time points for both groups. INLYTA + Avelumab is represented by a black line, and Sunitinib by a gray line.*

FDA Label Image

Figure 3 (Inlyta 04)

A Kaplan-Meier survival curve chart comparing overall survival (%) over time in months between two treatment arms: INLYTA plus pembrolizumab (black line) and sunitinib (gray line). The chart includes a risk table showing the number of patients at risk at different time points for each treatment.*

FDA Label Image

Figure 4 (Inlyta 05)

A Kaplan-Meier survival curve showing progression-free proportion over time (months) comparing INLYTA (axitinib) and Sorafenib. The graph plots progression-free proportion on the vertical axis and time in months on the horizontal axis, illustrating median progression-free survival of 6.7 months for INLYTA and 4.7 months for Sorafenib, with numerical hazard ratio and confidence interval information included.*

FDA Label Image

Logo (Inlyta 06)

FDA Label Image

Logo (Inlyta 07)

FDA Label Image

Principal Display Panel (1 mg Tablet Bottle Label)

The label for INLYTA 1 mg film-coated tablets contains axitinib as the active ingredient. The product is distributed by Pfizer Laboratories, a division of Pfizer Inc. The label shows storage instructions, quantity of 180 tablets, and highlights that it is a prescription drug. The label includes identifiers such as NDC, GTIN, and barcode, with a Pfizer logo and 'Made in Ireland' statement.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Label of Inlyta (axitinib) tablets 5 mg by Pfizer Laboratories. The film-coated oral tablet packaging contains 60 tablets. The label includes storage instructions, dosage references, barcodes, and distribution information stating it is made in Ireland by Pfizer Labs, division of Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.